Innovation

Researchers at Revel Pharmaceuticals enzymatically removed advanced glycation end product damage from aged human tissue for the first time, targeting the root molecular cause of aging rather than its symptoms. Meanwhile BioAge dosed its first patient using a drug discovered through longevity datasets, and longevity research is increasingly framed as a genuine US-China race. Here’s what this week’s aging research reveals.